Imaging During Subliminal Perception

NCT ID: NCT04643340

Last Updated: 2023-06-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

70 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-15

Study Completion Date

2022-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Subliminal perception of visual stimuli can be studied with functional brain imaging, e.g. with functional magnetic resonance imaging (fMRI). However, it is unclear how subliminal perception affects connectivity in the brain.

Further, it is not known if real-time (rt) fMRI neurofeedback of brain areas involved in subliminal perception can lead to supra-threshold perception.

For attention tasks, the investigators hypothesize that functional connectivity strength is mediated by the insular cortex during both supra-threshold and subliminal perception.

Additionally, the investigators hypothesize that rt-fMRI neurofeedback training should alter neuronal and behavioral responses.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this project, using healthy adults, the investigators have 2 aims:

1. Apply electroencephalography (EEG) and fMRI before and after rt-fMRI neurofeedback during attention tasks to identify brain regions involved in subliminal and supraliminal perception.
2. Apply functional connectivity analyses during these tasks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

active group 1

This group will train the insular cortex by real-time fMRI

real-time fMRI

Intervention Type OTHER

Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).

active group 2

This group will train the visual cortex by real-time fMRI

real-time fMRI

Intervention Type OTHER

Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).

sham

This group will only train the insula by a particular strategy

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

real-time fMRI

Brain regions can be trained, i.e. fMRI activity can be actively modulated online by humans, using rt-fMRI (Bruhl, Scherpiet et al. 2014, Bruhl 2015, Emmert, Kopel et al. 2016).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults (\> 18 \< 80 years), which can read and sign the informed consent form
* Male and female
* Right-handed

Exclusion Criteria

* metallic items in the body (i.e. eye splinter, MR incompatible implants)
* pacemaker
* claustrophobia
* pregnant participants
* participants suffering from a degenerative disorder of the Central Nervous System, such as Stroke, Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease and Huntington's Disease and with major psychiatric disorders such as schizophrenia, depression, or anxiety disorder
* Drug intake (psychopharmaca)
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Swiss National Science Foundation

OTHER

Sponsor Role collaborator

University of Zurich

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lars Michels, PhD

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Zürich

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Zurich

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-00483

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Attention and Visual Perception
NCT00111293 COMPLETED
Neurofeedback in Clinical High Risk
NCT06492343 NOT_YET_RECRUITING NA